Diferencias en las estadísticas de competición de tenis en los juegos olímpicos de Río de Janeiro 2016

This research aimed to explore the competition statistics at the Rio de Janeiro JJOO 2016. To this end, 282 sets of the 128 matches played were analysed; a total of 128 tennis players (64 players male and 64 players female) took part. Data have been selected of the published information on the Official Web of the International Tennis Federation (http://www.itftennis.com/olimpiadas/cuadros). Results showed that male gender obtained significant statistical values in the variables related to the service, while female gender obtained better values in variables related to the rest. With regard to the Laterality, no significant differences were found between left-handed and right-handed in the male gender. In the female gender the left-handed players obtained significantly higher values in the percentage of points won with the first and second serve, number of break points and number of points earned to the rest. The information obtained in this paper sets performance parameters that can be used to set targets and evaluate the performance of tennis players.El objetivo de este estudio fue conocer las estadísticas de competición de tenis en los JJOO de Río de Janeiro 2016. Para ello, se analizaron 282 sets de los 128 partidos en los que participaron un total de 128 tenistas (64 jugadores y 64 jugadoras). Los datos fueron seleccionados de la información publicada en la Web Oficial de la Federación Internacional de Tenis (http://www.itftennis.com/olimpiadas/cuadros). Los resultados mostraron que el género masculino obtuvo valores estadísticamente superiores en variables relacionadas con el servicio, mientras género femenino obtuvo mejores valores en variables relacionadas con el resto. Con respecto a la lateralidad, no se encontraron diferencias significativas entre zurdos y diestros en el género masculino. En el género femenino, las jugadoras zurdas obtuvieron unos valores significativamente superiores en el porcentaje de puntos ganados con el primer y segundo saque, número de puntos de break y número de puntos ganados al resto. La información obtenida en este trabajo establece unos parámetros de rendimiento que pueden resultar de utilidad para establecer objetivos y evaluar el rendimiento de los jugadores de tenis

Post-Transcriptional Regulation of BCL2 mRNA by the RNA-Binding Protein ZFP36L1 in Malignant B Cells

The human ZFP36 zinc finger protein family consists of ZFP36, ZFP36L1, and ZFP36L2. These proteins regulate various cellular processes, including cell apoptosis, by binding to adenine uridine rich elements in the 3′ untranslated regions of sets of target mRNAs to promote their degradation. The pro-apoptotic and other functions of ZFP36 family members have been implicated in the pathogenesis of lymphoid malignancies. To identify candidate mRNAs that are targeted in the pro-apoptotic response by ZFP36L1, we reverse-engineered a gene regulatory network for all three ZFP36 family members using the ‘maximum information coefficient’ (MIC) for target gene inference on a large microarray gene expression dataset representing cells of diverse histological origin. Of the three inferred ZFP36L1 mRNA targets that were identified, we focussed on experimental validation of mRNA for the pro-survival protein, BCL2, as a target for ZFP36L1. RNA electrophoretic mobility shift assay experiments revealed that ZFP36L1 interacted with the BCL2 adenine uridine rich element. In murine BCL1 leukemia cells stably transduced with a ZFP36L1 ShRNA lentiviral construct, BCL2 mRNA degradation was significantly delayed compared to control lentiviral expressing cells and ZFP36L1 knockdown in different cell types (BCL1, ACHN, Ramos), resulted in increased levels of BCL2 mRNA levels compared to control cells. 3′ untranslated region luciferase reporter assays in HEK293T cells showed that wild type but not zinc finger mutant ZFP36L1 protein was able to downregulate a BCL2 construct containing the BCL2 adenine uridine rich element and removal of the adenine uridine rich core from the BCL2 3′ untranslated region in the reporter construct significantly reduced the ability of ZFP36L1 to mediate this effect. Taken together, our data are consistent with ZFP36L1 interacting with and mediating degradation of BCL2 mRNA as an important target through which ZFP36L1 mediates its pro-apoptotic effects in malignant B-cells

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Collaborative research and actions on both sides of the US-Mexico border to counteract type 2 diabetes in people of Mexican origin

Abstract Background Type 2 Diabetes (T2D) is now a massive epidemic in both California and Mexico, with serious consequences for social and economic well-being. A large proportion of these populations share common ethnic backgrounds. Yet diverse environmental and social conditions across regions create unique opportunities to explore the ways that T2D risk, incidence, management and outcomes manifest. Main Text An action-oriented research consortium headed up by the University of California and Universidad Nacional Autónoma de Mexico was constituted to set priorities for bi-national translational research, in an attempt to implement and evaluate clinical, public health and policy actions to decrease the burden of T2D for people of Mexican origin. In this paper, we describe the epidemiology of T2D in Mexico and California, review current efforts to combat the epidemic, highlight gaps in knowledge and identify urgent areas of opportunity for collaboration. The group has developed a common research agenda and funding has been obtained to evaluate biological samples from the 2016 Mexican Health Survey, collaborate in a telemedicine-based retinopathy project, implement interventions in food banks, promote a communications campaign, and design a large-scale diabetes prevention effectiveness trial. Conclusions T2D has caused a state of emergency in Mexico and is a major health problem among Mexican populations on both sides of the border. Understanding the commonalities and differences between California and Mexico for those of Mexican origin with respect to T2D, when combined with a sharing of knowledge and advances, can produce a bi-national translational research agenda to inform relevant policy and practice. Amidst economic and political uncertainty and limited healthcare budgets, this collaboration can contribute to the development of scientific evidence to inform policies and interventions. This may provide a promising collaborative model that could be expanded to other health conditions and regions of the world

Collaborative research and actions on both sides of the US-Mexico border to counteract type 2 diabetes in people of Mexican origin.

BackgroundType 2 Diabetes (T2D) is now a massive epidemic in both California and Mexico, with serious consequences for social and economic well-being. A large proportion of these populations share common ethnic backgrounds. Yet diverse environmental and social conditions across regions create unique opportunities to explore the ways that T2D risk, incidence, management and outcomes manifest.Main textAn action-oriented research consortium headed up by the University of California and Universidad Nacional Autónoma de Mexico was constituted to set priorities for bi-national translational research, in an attempt to implement and evaluate clinical, public health and policy actions to decrease the burden of T2D for people of Mexican origin. In this paper, we describe the epidemiology of T2D in Mexico and California, review current efforts to combat the epidemic, highlight gaps in knowledge and identify urgent areas of opportunity for collaboration. The group has developed a common research agenda and funding has been obtained to evaluate biological samples from the 2016 Mexican Health Survey, collaborate in a telemedicine-based retinopathy project, implement interventions in food banks, promote a communications campaign, and design a large-scale diabetes prevention effectiveness trial.ConclusionsT2D has caused a state of emergency in Mexico and is a major health problem among Mexican populations on both sides of the border. Understanding the commonalities and differences between California and Mexico for those of Mexican origin with respect to T2D, when combined with a sharing of knowledge and advances, can produce a bi-national translational research agenda to inform relevant policy and practice. Amidst economic and political uncertainty and limited healthcare budgets, this collaboration can contribute to the development of scientific evidence to inform policies and interventions. This may provide a promising collaborative model that could be expanded to other health conditions and regions of the world

Recuperando evidencias en pacientes oncohematológicos (2ª parte): infección por catéter venoso y úlceras por presión

En el ámbito de la salud existe una enorme producción de conocimientos que no se aplican o utilizan. De esta forma, el desarrollo no está limitado por los descubrimientos, sino por su implantación. La necesidad de implantar evidencias está íntimamente unida con la de evaluar la repercusión real de su incorporación a los cuidados cotidianos; no sólo desde la perspectiva del “proceso” sino también la de los “resultados”. En nuestro campo uno de los resultados de salud más evaluados son los efectos adversos como la infección nosocomial y las ulceras por presión. Así, nos planteamos como objetivo localizar y resumir las evidencias sobre la infección por catéter venoso y la prevención de UPP, en una unidad de oncohematología, con el fin de facilitar su difusión e implantación de cambios en la práctica enfermera. Material y Método: La búsqueda comprendió los estudios publicados en inglés, francés y español sin límite de tiempo, en las bases de datos: CINAHL, MEDLINE, Cochrane Library, EMBASE, Pascal Biomed, LILACS, CUIDEN, CUIDEN cualitativa y CUIDATGE. Resultados: Los hallazgos más relevantes se dispusieron en formato de ficha-póster en el que se argumentaba la justificación de la importancia del problema clínico, la clasificación de niveles de evidencia utilizada, las recomendaciones y la propuesta de cambios en la práctica clínica a implementar. Este formato fue elegido para facilitar la transferencia de conocimiento en la práctica asistencial de la unidad. Los cambios propuestos surgieron del interior del equipo basándose en las evidencias encontradas. Esto supone un cambio de conductas y actitudes que creemos facilite la difusión de innovaciones. Abstract: There is an enormous knowledge base in the field of health which has no application. Its growth is not limited by its discovery but by the lack of its implementation. The necessity of implementing conclusions is evident in evaluating the real repercussion on quality daily cares; as “strategies” and “outcomes”. In talking about oncohematological nursing, some health outcomes would be: the reduction of adverse events such as nosocomial infections and pressure ulcers. Consequently, our objective has been: to find and summarize the evidences about Venous Catheterization and Pressure Ulcers; in order to encourage the spread of knowledge and promote changes in practice. Method: Databases as CINAHL, MEDLINE, Cochrane Library, EMBASE, Pascal Biomed, LILACS, CUIDEN, CUIDEN qualitative y CUIDATGE were revised in Spanish, French and English. No time restrictions were applied. Findings: The main findings and recommendations were synthesised on a poster, next to suggestions for practical changes to implement, evidence levels used, and the clinic problem significance. The suggested changes arose from nursing staff based on evidences found that includes behaviours and attitudes changes, which should facilitate more rapid innovations diffusion. Centro de Trabajo: (1) DUE. Unidad Oncohematologia, (2) DUE. M.Sc. Ciencias Enfermeras. Ph.D candidata. Consejería Sanidad Región Murcia, (3) Médico. Coordinador de Docencia. H.U. J.M. Morales Meseguer. (Murcia, España), (4) Bibliotecario. A. Laín Entralgo (Madrid, España) Fecha del Trabajo: 14/04/2008 Palabra Clave: Enfermería, Oncología, Enfermería Basada en la Evidencia, Cateterización venosa, Úlcera por presión. Key Words: Nursing, Oncohematology, Evidence-Based Nursing, Catheter-related infection, Pressure ulcer

Comparison between gene set enrichment validation results for ZFP36-inferred target genes obtained using different metrics of statistical-dependency.

<p>Abbreviations: KO, <i>Tis11/ZFP36</i> knock-out mouse fibroblasts; NES, normalised enrichment score from Kolmogorov-Smirnov gene set enrichment analysis; FDR, false discovery rate <i>q</i> value from Kolmogorov-Smirnov gene set enrichment analysis; MIC, maximum information coefficient; MI, mutual information, LR, linear regression coefficient.</p>a<p>Gene set representing 237 mRNAs displaying significant up-regulation in expression in fibroblasts from <i>Tis11/ZFP36</i>-deficient mouse fibroblasts <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0102625#pone.0102625-Ishmael1" target="_blank">[21]</a>.</p>b<p>Gene set representing 152 mRNAs displaying significantly decreased rate of degradation in <i>Tis11/ZFP36</i>-deficient mouse fibroblasts <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0102625#pone.0102625-Lai1" target="_blank">[22]</a>.</p

Modulation of ZFP36L1 expression levels is associated with changes in <i>BCL2</i> mRNA levels in different cell types.

<p>(A) Western blot analysis showing Zfp36L1 protein expression in wild-type, ZFP36L1 ShRNA and control empty lentivirus transduced BCL1 cells. Cell Signaling Technology rabbit-anti-human ZFP36L1/L2 antibody was used to detect Zfp36l1 expression. An anti-HSP90 antibody was used as a control for protein loading on the gel. (B) <i>BCL2</i> mRNA degradation analysis following actinomycin D treatment in Zfp36l1-knockdown and control murine leukemia BCL1 cells. qRT-PCR analysis of <i>Bcl2</i> mRNA levels over a 4 hour time course in control (empty lentivirus transduced BCL1 cells) and zfp36l1-knockdown BCL1 cells. Cells were treated with 5 µg/ml of actinomycin D for 0, 2, and 4 hours. The results are from 3 independent experiments and show mean ±SEM. * = p<0.05 as determined by student T test. (C) <i>ZFP36L1</i> and <i>BCL2</i> mRNA levels were measured by qRT-PCR in BCL1, ACHN and Ramos cells. Lentiviral mediated ZFP36L1 ShRNA was used to knockdown <i>ZFP36L1</i> mRNA levels in BCL1, ACHN and Ramos cells. qRT-PCR analysis was carried out as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0102625#s2" target="_blank">Methods</a>. Control cells were transduced with lentivirus containing scramble sequence (BCL1, ACHN) or empty lentivirus (Ramos). Mean ±SEM for triplicate samples are shown. These results are representative of at least 2 independent experiments done on each cell type. (D) BCL2 protein expression in ZFP36L1 ShRNA transduced or empty lentivirus (con) transduced Ramos cells. An anti-HSP90 antibody was used as a control for protein loading on the gel. (E) Following either ZFP36L1 or control siRNA oligonucleotide transfection, Ramos cells were treated with ionophore (A23187, 150 nM) and, 24 h later, MTT levels were measured. The results shown are from 4 independent experiments, mean ±SEM are shown. * = p<0.05 as determined by student T test.</p